These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 27273296)

  • 1. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
    Schmidt HH; Barroso F; González-Duarte A; Conceição I; Obici L; Keohane D; Amass L
    Muscle Nerve; 2016 Sep; 54(3):353-60. PubMed ID: 27273296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
    Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
    Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
    Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
    Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
    Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
    Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.
    Obici L; Kuks JB; Buades J; Adams D; Suhr OB; Coelho T; Kyriakides T;
    Curr Opin Neurol; 2016 Feb; 29 Suppl 1(Suppl 1):S27-35. PubMed ID: 26734953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
    Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y
    J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transthyretin familial amyloid polyneuropathy].
    Kopishinskaya SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(10):82-89. PubMed ID: 30499502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.
    Conceição I; González-Duarte A; Obici L; Schmidt HH; Simoneau D; Ong ML; Amass L
    J Peripher Nerv Syst; 2016 Mar; 21(1):5-9. PubMed ID: 26663427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy.
    Leibou L; Frand J; Sadeh M; Lossos A; Kremer E; Livneh A; Yarnitsky D; Herman O; Dabby R
    Isr Med Assoc J; 2012 Nov; 14(11):662-5. PubMed ID: 23240369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.
    Jimenez-Zepeda VH; Bahlis NJ; Gilbertson J; Rendell N; Porcari R; Lachmann HJ; Gillmore JD; Hawkins PN; Rowczenio DM
    Amyloid; 2015 Mar; 22(1):26-30. PubMed ID: 25430583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
    Chaves M; Bettini M; Marciano S; Sáez S; Cristiano E; Rugiero M
    Medicina (B Aires); 2016; 76(2):105-8. PubMed ID: 27135849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review.
    Martens B; De Pauw M; De Bleecker JL
    Acta Neurol Belg; 2018 Jun; 118(2):179-185. PubMed ID: 29524093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Familial amyloid polyneuropathy].
    Yamashita T; Ando Y; Uchino M
    Brain Nerve; 2011 Jun; 63(6):583-95. PubMed ID: 21613661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?
    Adams D; Beaudonnet G; Adam C; Lacroix C; Théaudin M; Cauquil C; Labeyrie C
    Rev Neurol (Paris); 2016 Oct; 172(10):645-652. PubMed ID: 27663057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy.
    Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y
    J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial amyloidotic polyneuropathy and transthyretin.
    Nagasaka T
    Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.
    Li H; Zhang Y; Cao L; Xiong R; Zhang B; Wu L; Zhao Z; Chen SD
    Drug Des Devel Ther; 2014; 8():2121-8. PubMed ID: 25382970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan.
    Miyake Z; Nakamagoe K; Ezawa N; Yoshinaga T; Hashimoto R; Sato T; Sekijima Y; Tamaoka A
    Intern Med; 2019 Mar; 58(5):713-718. PubMed ID: 30333406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.